An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects

You may not be if

• Co-existing Condition:
• Patients with the following conditions or symptoms are excluded:
• Oral candida infection documented by morphology or by response to antifungal therapy within 2 months prior to study entry.
• Temperature \> 37.8 degrees Centigrade.
• Malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ.
• Significant chronic underlying medical illnesses which would prevent continuous participation in this clinical trial.
• Concurrent Medication:
• Excluded:
• \-
• Patients with the following are excluded:
• Significant chronic underlying medical illnesses which would prevent continuous participation in this clinical trial.
• Unwilling to sign informed consent.
• Intolerant to zidovudine (AZT).
• Oral hairy leukoplakia at any time prior to study entry.
• Prior Medication:
• Excluded within 7 days of study entry:
• Antiretroviral drugs.
• Immunomodulators.
• Excluded within 30 days of study entry:
• Any investigational drugs.
• Patients have the following:
• HIV seropositivity by licensed ELISA test, confirmed by Western Blot analysis.
• No symptoms as defined by:
• 1. Normal neurological exam.
• 2. Absence of the following:
• Unintentional weight loss of greater than 10 pounds or more than 10 percent of usual body weight within 2 months prior to study entry.
• Unexplained temperature \> 37.8 C on more than 5 consecutive days or on more than 10 days in any 30 day period in the one month prior to expected study entry.
• Unexplained diarrhea defined by = or \> 3 liquid stools per day persisting \> 7 days within 2 months prior to expected study entry.